Wilke, Celine

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 2,622

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 362

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

Chi, K. N., Armstrong, A. J., Krause, B. J., Herrmann, K., Rahbar, K., de Bono, J. S., Adra, N., Garje, R., Michalski, J. M., Kempel, M. M., et al. (2024) · European Urology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 37

Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.

Krause, B. J., Chi, K. N., Sartor, A. O., Fizazi, K., Morris, M. J., De Bono, J. S., Tagawa, S. T., Herrmann, K., Kurth, J., Eiber, M., et al. (2023) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 11